Effects of ectopic HER-2/neu gene expression on the COX-2/PGE 2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Li, Shu ^a   Ma, Xiaoxin ^a   Ma, Li ^a   Wang, Cuicui ^a   He, Yuanqi ^a   Yu, Zhijuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Endometrial carcinoma cell; Estradiol; HER 2 neu; P450arom

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTAGLANDIN E2;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ENDOMETRIUM CARCINOMA; EXPRESSION VECTOR; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNODETECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AROMATASE; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84874398427     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-11     Document Type: Article

References (21)

1. Le J, Obstetrics and Gynecology [M] China: Beijing: Beijing People's Medical Publishing House 6 2005 300
2. Cyclooxygenase-2 is essential for HER2/neu tosuppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Simeone AM, Li YJ, Broemeling LD, Cancer Res 2004 64 4 1224 1228 10.1158/0008-5472.CAN-03-2188 14973114 (Pubitemid 38235585)
3. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Wang SC, Lien HC, Xia W, Cancer Cell 2004 6 3 251 261 10.1016/j.ccr.2004.07.012 15380516 (Pubitemid 39222038)
4. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Faltus T, Yuan J, Zimmer, Krämer A, Loibl S, Kaufmann M, Strebhardt K, Neoplasia 2004 6 6 786 795 10.1593/neo.04313 15720805 (Pubitemid 40041497)
5. Epidermalgrowth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Tiseo M, Loprevite M, Ardizzoni A, CurrMed Chem Anti-Canc Agents 2004 4 2 139 148 10.2174/1568011043482106 (Pubitemid 38404689)
6. Stage-and tissue-specific expression of neu oncogene in rat development. Kokay Y, Cohen JA, Proc Natl Acad Sci USA 1987 84 8498 10.1073/pnas.84.23.8498 3317411
7. Expression of protein c-erbb-2 in endometrial diseases and clinical significance testis neoplasms. Xiao-xin M, Qing M, China Journal of Modern Medicine 2006 16 4 550 552
8. Effects of HER2 on COX-2/PGE2 /P450arom Signal Pathway in Nude Mice Endometial Model. Yuan-qi HE, Xiao-xin MA, Shu LI, The Journal of China Medical University 2010 39 10 823 826
9. Loss of R ALT/M IG -6expression in ER BB2-amplified breastcarcinom as enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Anastasi S, SALA G, Huiping C, Oncogene 2005 24 4540 4548 10.1038/sj.onc.1208658 15856022 (Pubitemid 41032617)
10. Dual role of A P-2 gamma in ErbB-2-induced mammary tumorigenesis. Jager R, Friedrichs N, Heim I, Breast Cancer Res Treat 2005 90 3 273 280 10.1007/s10549-004-4815-x 15830141 (Pubitemid 40576841)
11. High-dose alkylating agents with autologous hem atopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: afeasibility study. Goncalves A, BRA DAC, Vire F, A nticancer Res 2005 25 1B 663 667 (Pubitemid 40470079)
12. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Essapen S, Thomas H, Green M, Int J On-col 2004 24 2 241 248
13. HER -2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Half E, Broaddus R, Danenberg KD, Int J Cancer 2004 108 4 540 548 10.1002/ijc.11599 14696118 (Pubitemid 38036654)
14. Regulation of cyclooxygenase-2 pathway by HER-2 receptor. Ratna V, Mahitosh M, Liana A, Oncogene 1999 18 2 305 314 10.1038/sj.onc.1202307 9927187 (Pubitemid 29060606)
15. Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Wang KH, Kao AP, Chang CC, Mole Cancer 2010 9 288 10.1186/1476-4598-9-288
16. Multiple roles of cy-clooxygenase-2 inendometrial cancer. Ohno S, Ohno Y, Suzuki N, Anticancer Res 2005 25 6A 3679 3687 16323359 (Pubitemid 41658439)
17. Aromatase-key enzyme of estrogen biosynthesis. Milczarek R, Klimek J, Postepy Biochem 2005 51 4 430 439 16676578
18. Stimulation of aromatase P450 promoter (II)activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of SF-1 and COUP-TF to the same cis-acting element. Zeitoun KM, Takayama K, Michael MD, Mol Endocrinol 1999 13 239 253 10.1210/me.13.2.239 9973254 (Pubitemid 29067999)
19. The role of the epidermal growth factor receptor in breast cancer. Chan SK, Hill ME, Gullick WJ, J Mammary Gland Biol Neoplasia 2006 11 1 3 11 10.1007/s10911-006-9008-2 16947082 (Pubitemid 44309185)
20. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Livasy CA, Reading FC, Moore DT, Gynecol Oncol 2006 100 1 101 106 10.1016/j.ygyno.2005.07.124 16157366 (Pubitemid 41815057)
21. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Ejskjaer K, Sorensen BS, Poulsen SS, Gynecol Oncol 2007 104 1 158 167 10.1016/j.ygyno.2006.07.015 16962163 (Pubitemid 46054118)